ZEO ScientifiX Secures Strategic Position as Official Regenerative Medicine Educational Partner for A4M at Longevity SpringFest 2026

Key Developments and Strategic Implications for Shareholders

FORT LAUDERDALE, Fla., March 31, 2026 — ZEO ScientifiX, Inc. (OTCQB: ZEOX), a clinical-stage biopharmaceutical and biotechnology company, has announced a potentially transformative agreement solidifying its role as the Official Regenerative Medicine Educational Partner with the American Academy of Anti-Aging Medicine (A4M) at the upcoming Longevity SpringFest 2026.

Key Highlights

• Exclusive Educational Role: ZEO will act as the “official arm of education” for regenerative medicine at A4M, one of the world’s largest anti-aging medical associations. This partnership notably grants ZEO direct and exclusive access to A4M’s network of approximately 26,000 physicians and healthcare practitioners in over 120 countries.
• High-Profile Masterclass: ZEO will host a specialized, full-day Masterclass on April 9, 2026, in West Palm Beach, Florida. This training will deliver evidence-based, advanced regenerative medicine education to medical professionals, setting a new standard in the sector.
• Strategic Industry Positioning: ZEO is now aligned with other publicly traded longevity leaders such as Niagen Bioscience (NASDAQ: NAGE) and InBody (KRX: 041830), reinforcing its status within the estimated \$29.9 billion global longevity therapy market (The Business Research Company, 2026).
• Prestigious Leadership: The Masterclass will be chaired by Dr. George C. Shapiro, MD, Chief Medical Officer of ZEO, who emphasized the importance of establishing rigorous, evidence-based standards for the training of regenerative medicine clinicians.

Detailed Program Overview

• Scientific Foundations: The Masterclass will cover the differentiation between cellular versus acellular biologics and highlight manufacturing quality standards.
• Clinical Integration: Real-world applications will be discussed, focusing on musculoskeletal, orthopedic, and oncology-adjacent care.
• Regulatory Compliance: Attendees will be guided through both federal and Florida-specific biologic legislation to ensure complete regulatory adherence.

Company Overview

ZEO ScientifiX, Inc. operates from Nova Southeastern University’s \$100 million Center of Collaborative Research. The company is focused on developing and manufacturing regenerative biologics, aiming to translate innovative science into scalable and commercially viable clinical solutions. More information can be found at https://zeoscientifix.com.

Potential Impact on Shareholders and Share Price Sensitivity

• Market Visibility & Strategic Access: By becoming the official educational partner for A4M, ZEO gains substantial visibility and credibility among thousands of global medical professionals. This could drive increased adoption of ZEO’s products and services, positioning the company as a leader in the high-growth regenerative medicine sector.
• Competitive Differentiation: The association with high-profile partners like A4M, Niagen Bioscience, and InBody sets ZEO apart from smaller or less integrated biotech firms, potentially making ZEO more attractive to investors seeking exposure to the longevity and regenerative medicine markets.
• Scalability & Revenue Potential: Direct access to a vast practitioner network opens significant opportunities for ZEO to scale clinical solutions and expand its customer base, which may translate into increased revenue streams and, consequently, shareholder value.
• Regulatory and Educational Leadership: Leading the educational standards in a highly regulated and rapidly evolving field could cement ZEO’s reputation as a standard-bearer, potentially supporting long-term share price appreciation.

Forward-Looking Statements and Risks

The company notes that forward-looking statements in this announcement are subject to risks and uncertainties. Actual performance and results may differ materially from current expectations. ZEO disclaims any obligation to update these statements in the future.

Investor Relations Contact

Karlista Maroney
Director of Growth Strategy
Email: [email protected]

Disclaimer: This article is for informational purposes only and does not constitute an offer to buy or sell any securities. Investors should conduct their own due diligence before making investment decisions. Forward-looking statements are subject to change and actual results may differ.

View Zeo ScientifiX, Inc. Historical chart here